PUBLISHER: KBV Research | PRODUCT CODE: 1431201
PUBLISHER: KBV Research | PRODUCT CODE: 1431201
The Asia Pacific Tissue Diagnostics Market would witness market growth of 10.0% CAGR during the forecast period (2023-2030).
Tissue diagnostics is integral in studying infectious diseases. It aids in identifying pathogens, assessing tissue damage, and monitoring treatment responses. Autoimmune disorders and inflammatory conditions also benefit from tissue diagnostics, providing insights into the underlying mechanisms of immune system dysfunction and guiding appropriate therapeutic interventions.
Neuropathology is another critical area where tissue diagnostics plays a pivotal role. Examining brain and nervous tissue samples helps diagnose neurological disorders, assess the extent of damage, and guide neurosurgical interventions. Furthermore, it contributes to organ transplantation by ensuring compatibility and assessing the condition of donor organs. Moreover, digital pathology is gaining prominence, allowing for the digitization of histopathology slides. This shift from traditional microscopy to digital platforms enhances collaboration, facilitates remote consultations, and enables the integration of artificial intelligence (AI) algorithms for image analysis. AI applications in tissue diagnostics hold the potential to improve diagnostic accuracy, reduce turnaround times, and enhance overall efficiency.
The growing pharmaceutical industry in India is increasingly emphasizing precision medicine and personalized therapies. It plays a crucial role in precision medicine by providing detailed molecular information about a patient's disease, enabling the tailoring of treatment strategies to individual characteristics. As per the data from the India Brand Equity Foundation, by 2030, it is anticipated that the Indian pharmaceutical industry will have a total market size of $130 billion. By FY25, the domestic pharmaceutical industry is projected to generate 57 billion US dollars in revenue and experience an operating margin expansion of 100 to 150 basis points.
The China market dominated the Asia Pacific Tissue Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $668 million by 2030. The Japan market is registering a CAGR of 9.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 10.7% during (2023 - 2030).
Based on Product, the market is segmented into Consumables (Antibodies, Kits, Reagents, Probes), and Instruments (Slide-staining Systems, Scanners, Tissue Processing Systems, Others). Based on Technology, the market is segmented into Immunohistochemistry, In Situ Hybridization, Digital Pathology & Workflow, and Special Staining. Based on Disease Type, the market is segmented into Breast Cancer, Lymphoma, Prostate Cancer, Gastric Cancer, Non-small Cell Lung Cancer, and Others. Based on End User, the market is segmented into Hospitals, Research Laboratories, Pharmaceutical Organizations, Contract Research Organizations (CROs), and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled